You are here

The International Journal of Biological Markers

The International Journal of Biological Markers

2017 Impact Factor: 1.449
2017 Ranking: 203/222 in Oncology | 120/160 in Biotechnology & Applied Microbiology
Source: Journal Citation Reports®, 2018 release, a Clarivate Analytics product; Indexed in PubMed: MEDLINE

Editor in Chief
Dr. Massimo Gion Regional Center for Biomarkers, Italy
Co-Editors
Dr. Maria Grazia Daidone National Cancer Institute, Foundation and IRCCS, Italy
Prof. Giampietro Gasparini Cancer Institute IRCCS "Giovanni Paolo II", Italy
Prof. Robin Leake University of Glasgow, United Kingdom
Prof. Masakazu Toi OOTR Institute Kyoto, Japan
Founding Editor
Dr. Emilio Bombardieri Humanitas Gavazzeni, Italy


eISSN: 17246008 | ISSN: 17246008 | Current volume: 33 | Current issue: 3 Frequency: Quarterly

From 1st January 2019, The International Journal of Biological Markers (IJBM) will become a fully open access journal.

To facilitate this transition, all articles first submitted on or after 1st September 2018 will be subject to an introductory article processing charge (APC) of $1500 USD (plus tax where applicable) discounted from the full rate of $2000 USD for a limited time. All articles will be published under a Creative Commons licence. The APC will be payable on acceptance if the article is accepted after peer review.

The International Journal of Biological Markers (IJBM) is an international, online only, peer-reviewed Journal, which publishes original research and critical reviews primarily focused on cancer biomarkers.

IJBM targets advanced topics regarding the application of biomarkers in oncology and is dedicated to solid tumors in adult subjects. The clinical scenarios of interests are screening and early diagnosis of cancer, prognostic assessment, prediction of the response to and monitoring of treatment. The journal is interested in the publication of studies aimed at validation of biomarkers for clinical application.

In addition, IJBM focuses on research areas that facilitate translational research on biomarkers, such as knowledge translation, bio-banking, biostatistics and method validation and standardization.

The International Journal of Biological Markers (IJBM) is an international, online only, peer-reviewed Journal, which publishes original research and critical reviews primarily focused on cancer biomarkers.

IJBM targets advanced topics regarding the application of biomarkers in oncology and is dedicated to solid tumors in adult subjects. The clinical scenarios of interests are screening and early diagnosis of cancer, prognostic assessment, prediction of the response to and monitoring of treatment. The journal is interested in the publication of studies aimed at validation of biomarkers for clinical application.

In addition, IJBM focuses on research areas that facilitate translational research on biomarkers, such as knowledge translation, bio-banking, biostatistics and method validation and standardization.

Subject Area Editor - Gastrointestinal and Pancreatic Cancer
Prof. Nadir Arber Tel Aviv Medical Centre, Israel
Prof. Stefano Cascinu University of Modena, Italy
Dr. Stephan L. Chan Chinese University of Hong Kong, China
Prof. Massimo Falconi Universita Vita e Salute San Raffaele Ospedale San Raffaele IRCCS, Italy
Subject Area Editor - Clinical Laboratory
Prof. Vivian Barak Hadassah Medical Center, Israel
Dr. Mario Correale IRCCS DE BELLIS, Italy
Dr. Ruggero Dittadi Ospedale dell'Angelo, Italy
Dr. Rafael Molina Biomedical Diagnostic Center, Spain
Prof. Mario Plebani University of Padua, Italy
Subject Area Editor - Gynecological Cancer
Dr. Robert C. Bast, Jr MD Anderson Cancer Centre, United States
Prof. Tiziano Maggino Ospedale dell'angelo Mestre, Italy
Prof. Paolo Zola Città della Salute e della Scienza" University Hospital, Italy
Subject Area Editor - Urological Cancer
Prof. Francesco Boccardo University of Genoa, Italy
Prof. Antonio Lopez-Beltran University of Cordoba, Spain
Prof. Rodolfo Montironi Polytechnic University of the Marche Region, Italy
Samantha Salvi Istituto scientifico Romagnolo per lo Studio e la Cura dei tumori (IRST) IRCCS, Italy
Prof. Axel Semjonow University Hospital Münster, Germany
Subject Area Editor - Statistics and Research Methodology
Prof. Patrizia Boracchi University of Milan, Italy
Dr. Luigi Mariani Fondazione IRCCS Istituto Nazionale Tumori, Italy
Dr. Valter Torri Mario Negri Institute IRCCS, Italy
Subject Area Editor - Clinical and Molecular Epidemiology
Dr. Paolo Bruzzi National Cancer Research Institute, Italy
Prof. Paola Muti McMaster University, Canada
Dr. Marco Zappa Institute for Study and Prevention of Cancer (ISPO), Italy
Subject Area Editor - Prognostic/Predictive Markers
Prof. Jennifer Byrne Kids Research Institute (KRI), Australia
Prof. Xichun Hu Fudan University Shanghai Cancer Center, China
Prof. Rosella Silvestrini National Cancer Institute, Foundation and IRCCS, Italy
Subject Area Editor - Pathology
Dr. Antonino Carbone IRCCS CRO Aviano and A.O., Italy
Prof. Paola Cassoni University of Turin, Italy
Prof. Hironobu Sasano Tohoku University Hospital, Japan
Subject Area Editor - Targeted Therapies
Prof. Louis WC Chow Organisation for Oncology and Translational Research, China
Dr. Stefan Glück University of Miami, United States
Subject Area Editor - Basic and Preclinical Research
Dr. Elda Tagliabue National Cancer Institute, Foundation and IRCCS, Italy
Prof. Michele De Bortoli University of Turin, Italy
Subject Area Editor - Melanoma and Sarcoma
Prof. Carlo Riccardo Rossi University of Padua, Italy
Subject Area Editor - Mesothelioma
Dr. Marcello Deraco Fondazione IRCCS Istituto Nazionale Tumori, Italy
Subject Area Editor - Lung Cancer
Prof. Massimo Di Maio University of Turin, Italy
Prof. Maria Planck Lund University, Sweden
Prof. Giorgio Vittorio Scagliotti University of Turin, Italy
Prof. Yi-long Wu Guangdong General Hospital, China
Subject Area Editor - Microenvironment & Immunology
Dr. Aline S.C. Fabricio Regional Centre for Biomarkers, Italy
Dr. Valter Gattei CRO-National Cancer Institute, Italy
Prof. Douglas Noonan University of Insubria, Italy
Subject Area Editor - Neuro-Oncology
Prof. Manuel Graeber University of Sydney Brain and Mind Centre, Australia
Subject Area Editor - Biospecimens & Biorepositories
Dr. Fiorella Guadagni IRCCS San Raffaele Pisana, Italy
Subject Area Editor - Hepatobiliary Tract Cancer
Dr. Etsuro Hatano Kyoto University, Japan
Prof. Patrizia Pontisso University of Padua, Italy
Subject Area Editor - Breast Cancer
Prof. Chiun-Sheng Huang National Taiwan University Hospital, China
Dr. Giorgio Secreto National Cancer Institute, Foundation and IRCCS, Italy
Prof. Binghe Xu Chinese Academy of Medical Sciences, China
Subject Area Editor - Biomarkers and Imaging Integration
Prof. Giuseppe Madeddu University of Sassari, Italy
Dr. Domenico Rubello Santa Maria della Misericordia Hospital, Italy
Prof. Marco Salvatore University of Naples Federico II, Italy
Subject Area Editor - Head and Neck Cancer
Prof. Gino Marioni University of Padua, Italy
Subject Area Editor - Biomarker Discovery (-omics)
Dr. Pierluigi Mauri Institute for Biomedicl Technologies (ITB-CNR), Italy
Dr. Maria Pasic St. Joseph's Health Centre, Canada
Subject Area Editor - Liquid Biopsies
Prof. Kevin Spring Western Sydney University, Australia
Subject Area Editor - Knowledge Translation and Appropriateness
Dr. Parvin Tajik University of Amsterdam, Netherlands
Dr. Chiara Trevisiol Veneto Institute of Oncology IOV-IRCCS, Italy
Subject Area Editor - Molecular Diagnostics and Pharmacogenomics
Dr. Giuseppe Toffoli CRO-National Cancer Institute, Italy
Prof. Theoni Trangas University of Ioannina, Greece
  • CNKI Scholar
  • Clarivate Analytics: BIOSIS Previews
  • Clarivate Analytics: Biological Abstracts
  • Clarivate Analytics: Current Contents - Clinical Medicine
  • Clarivate Analytics: Current Contents - Life Sciences
  • Clarivate Analytics: Science Citation Index Expanded
  • EBSCO Discovery Service
  • Embase
  • J-Gate
  • Journal Citation Reports/Science Edition
  • Ovid
  • PubMed: MEDLINE
  • Scopus
  • Manuscript Submission Guidelines: The International Journal of Biological Markers

    This Journal is a member of the Committee on Publication Ethics

    This Journal recommends that authors follow the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals formulated by the International Committee of Medical Journal Editors (ICMJE).

    Please read the guidelines below then visit the Journal’s submission site https://mc.manuscriptcentral.com/tijbm to upload your manuscript. Please note that manuscripts not conforming to these guidelines may be returned.

    Only manuscripts of sufficient quality that meet the aims and scope of The International Journal of Biological Markers will be reviewed.

    As part of the submission process you will be required to warrant that you are submitting your original work, that you have the rights in the work, that you are submitting the work for first publication in the Journal and that it is not being considered for publication elsewhere and has not already been published elsewhere, and that you have obtained and can supply all necessary permissions for the reproduction of any copyright works not owned by you.

    Any correspondence, queries or additional requests for information on the manuscript submission process should be sent to Dr. Antonette Leon at The International Journal of Biological Markers editorial office as follows: journal.biomarkers@aulss3.veneto.it

    1. Open Access
    2. Article processing charge (APC)
    3. What do we publish?
      3.1 Aims & Scope
      3.2 Article types
      3.3 Writing your paper
    4. Editorial policies
      4.1 Peer review policy
      4.2 Authorship
      4.3 Acknowledgements
      4.4 Funding
      4.5 Declaration of conflicting interests
      4.6 Research ethics and patient consent
      4.7 Clinical trials
      4.8 Reporting guidelines
      4.9 Data
    5. Publishing policies
      5.1 Publication ethics
      5.2 Contributor's publishing agreement
    6. Preparing your manuscript
      6.1 Formatting
      6.2 Artwork, figures and other graphics
      6.3 Supplementary material
      6.4 Reference style
      6.5 English language editing services
    7. Submitting your manuscript
      7.1 Title, keywords and abstracts
      7.2 Information required for completing your submission
      7.3 ORCID
      7.4 Permissions
    8. On acceptance and publication
      8.1 SAGE Production
      8.2 Online First publication
      8.3 Promoting your article
    9. Further information

    This Journal is a member of the Committee on Publication Ethics.

    This Journal recommends that authors follow the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals formulated by the International Committee of Medical Journal Editors (ICMJE).

    Please read the guidelines below then visit the journal’s submission site https://mc.manuscriptcentral.com/tijbm to upload your manuscript. Please note that manuscripts not conforming to these guidelines may be returned. 

    Only manuscripts of sufficient quality that meet the aims and scope of The International Journal of Biological Markers will be reviewed.

    As part of the submission process you will be required to warrant that you are submitting your original work, that you have the rights in the work, that you are submitting the work for first publication in the Journal and that it is not being considered for publication elsewhere and has not already been published elsewhere, and that you have obtained and can supply all necessary permissions for the reproduction of any copyright works not owned by you.

    1. Open Access

    The International Journal of Biological Markers is an open access, peer-reviewed journal. Each article accepted by peer review is made freely available online immediately upon publication, is published under a Creative Commons license and will be hosted online in perpetuity. Publication costs of the journal are covered by the collection of article processing charges which are paid by the funder, institution or author of each manuscript upon acceptance. There is no charge for submitting a paper to the journal. 

    For general information on open access at SAGE please visit the Open Access page or view our Open Access FAQs

    2. Article processing charge (APC)

    If, after peer review, your manuscript is accepted for publication, a one-time article processing charge (APC) is payable. This APC covers the cost of publication and ensures that your article will be freely available online in perpetuity under a Creative Commons license. 

    From 1st January 2019, The International Journal of Biological Markers will become a fully open access journal. 

    To facilitate this transition, all articles first submitted on or after 1st September 2018 will be subject to an introductory article processing charge (APC) of $1500 USD (plus tax where applicable) discounted from the full rate of $2000 USD for a limited time. All articles will be published under a Creative Commons license. The APC will be payable on acceptance if the article is accepted after peer review.

    Back to top
     

    3. What do we publish?

    3.1 Aims & Scope

    Before submitting your manuscript to The International Journal of Biological Markers, please ensure you have read the Aims & Scope.

    3.2 Article Types

    Original research articles

    Previously unpublished manuscripts, describing clinical, pre-clinical, epidemiological investigations, clinical trials, clinical observations, and other relevant investigations that are based on sound patient series, validated analytical methods, and appropriate statistical evaluation.

    Original research articles should be structured as follows: Introduction (clearly stating an objective or hypothesis), Methods (describing the study design and methods applied, including the study setting and dates, patients or participants with inclusion and exclusion criteria, and/or participation or response rates, or data sources, and how these were selected for the study), Results (describing the results of the study in context with the published literature and addressing study limitations), and Discussion (addressing relevant implications for clinical practice or health policy). A structured abstract is required.

    Words: max 3000 (excluding figures and tables)
    Figures/Tables: max 5
    References: max 50

    Clinical trial protocols

    A clinical trial is defined as any research project that prospectively assigns human participants to intervention or comparison groups to study the cause-and-effect relationship between an intervention and a health outcome. Each manuscript should be divided as follows: Introduction (stating an objective or hypothesis of the protocols), Methods (describing the design and statistical methods applied, including the study setting and dates, patients or participants with inclusion and exclusion criteria), Results (including data on recruitment, etc.), and Discussion (placing the protocol in context with the published literature). A structured abstract is required, and trial registration information (name, number, and URL) must be listed in the title page.

    Words: max 3000 (excluding figures and tables)
    Figures/Tables: max 6
    References: max 50

    Reviews

    Reviews are solicited by the Editor in Chief on topics that are deemed to be relevant to the audience of the Journal. Containing the current state of knowledge or practice, integrating recent advances with accepted principles and practice, or summarizing and analyzing consensus view of controversial issues in knowledge of practice. A non-structured abstract is required.

    Words: max 5000 (excluding figures and tables)
    Figures/Tables: max 5
    References: no limit

    Editorials

    The purpose of the editorials is to provide the reader with a balanced overview of relevant and up to date subjects concerning the Journal's aim or future direction. A non-structured abstract is not required.

    Words: max 1500 (excluding figures and tables)
    Figures/Tables: max 2
    References: max 15

    Technical briefs

    Technical briefs are papers on methodological comparisons, new method development or other methodological approaches. They should have a short Introduction, Methods, Results and a brief Conclusion.

    Words: max 3000 (excluding figures and tables)
    Figures/Tables: max 5
    References: max 20

    Short communications

    This article type reports of results from original researches. They must provide conclusive findings: preliminary observations or incomplete findings cannot be considered for publication. A non-structured abstract is required.

    Words: max 2000 (excluding figures and tables)
    Figures/Tables: max 3
    References: max 20

    Case reports

    Case reports will be accepted if they describe a previously undescribed clinical case and are of very high importance for dissemination. Case reports must be structured as follows: Introduction (explaining the importance of the case), Case Description (providing all relevant information), and Conclusions (describing the detailed outcome of the report). A structured abstract is required.

    Words: max 2000 (excluding figures and tables)
    Figures/Tables: max 3
    References: max 10

    Correspondence

    Letters to the Editor are intended to present opinions or comments on articles published in the Journal. Letters are subject to abridgement and editing for style and content. An abstract is not required.

    If you are the corresponding author of an article cited in a Letter to the Editor and receive an email invitation to comment on it, you must log in to the system, accept the invitation immediately, and then upload and submit your reply to the Editorial Office. The response must cite the title of the letter, e.g., “Response to (Title of Letter)”.

    Words: max 750 (excluding figures and tables)
    Figures/Tables: 1
    References: max 5

    3.3 Writing your paper

    The SAGE Author Gateway has some general advice and on how to get published, plus links to further resources.

    3.3.1 Make your article discoverable

    When writing up your paper, think about how you can make it discoverable. The title, keywords and abstract are key to ensuring readers find your article through search engines such as Google. For information and guidance on how best to title your article, write your abstract and select your keywords, have a look at this page on the Gateway: How to Help Readers Find Your Article Online

    Back to top

    4. Editorial policies

    4.1 Peer review policy

    Manuscripts that do not adhere to the guidelines for submission will be returned to the corresponding author for technical revision before undergoing the peer review process. Manuscripts with insufficient priority for publication will be rejected promptly.

    Peer review is the process we use to assess the quality of a manuscript to see if it suitable for publication. Independent researchers with similar competencies assess submitted manuscripts for originality, validity and importance to help our Editors determine if a manuscript is suitable for publication in their journal.

    We utilise a single-blind peer-review system, which is considered to be self-regulating. Reviewers are aware of the names and affiliations of the authors, but the reviewer assessments provided to authors are completely anonymous. The single-blind peer review system is the most commonly-used method of review and most Reviewers are comfortable with this approach, as it facilitates an impartial appraisal of a manuscript.

    Submitted manuscripts are reviewed by two or more referees who evaluate whether the manuscript is scientifically logical and well-constructed, focussing specifically on if it duplicates previously published work, and if there are clear grounds for it to be considered for publication. The Editors establish their decision based on these reports and, if necessary, they can discuss with members of the Editorial Board.

    We aim to provide authors with a first decision (of accept, reject or revisions required whether minor or major) within 4 weeks.

    All correspondence related to the submission, including editorial decisions, will be sent by email to the corresponding author. In case of revision, detailed revision instructions will be sent and a point-by-point response will be required. The Journal does not reveal the identity of its reviewers.

    Authors can check the status of their manuscript at any time by logging into the journal's submission system, SAGE track.

    Appeals and complaints
    If you would like to appeal a rejection decision or make a complaint, please contact the Publisher who will outline the journal's complaints procedure.

    As part of the submission process you will be asked to provide the names of a minimum of 2 peers who could be called upon to review your manuscript. Recommended reviewers should be experts in their fields and should be able to provide an objective assessment of the manuscript. Please be aware of any conflicts of interest when recommending reviewers. Examples of conflicts of interest include (but are not limited to) the below:

    • The reviewer should have no prior knowledge of your submission
    • The reviewer should not have recently collaborated with any of the authors
    • Reviewer nominees from the same institution as any of the authors are not permitted

    You will also be asked to nominate peers who you do not wish to review your manuscript (opposed reviewers).

    Please note that the Editors are not obliged to invite/reject any recommended/opposed reviewers to assess your manuscript.

    The Editor or members of the Editorial Board may occasionally submit their own manuscripts for possible publication in the journal. In these cases, the peer review process will be managed by alternative members of the Board and the submitting Editor/Board member will have no involvement in the decision-making process.

    The International Journal of Biological Markers is committed to delivering high quality, fast peer-review for your paper, and as such has partnered with Publons. Publons is a third party service that seeks to track, verify and give credit for peer review. Reviewers for Journal Title can opt in to Publons in order to claim their reviews or have them automatically verified and added to their reviewer profile. Reviewers claiming credit for their review will be associated with the relevant journal, but the article name, reviewer’s decision and the content of their review is not published on the site. For more information visit the Publons website.

    4.2 Authorship

    Papers should only be submitted for consideration once consent is given by all contributing authors. Those submitting papers should carefully check that all those whose work contributed to the paper are acknowledged as contributing authors.

    The list of authors should include all those who can legitimately claim authorship. This is all those who:

    • Made a substantial contribution to the concept or design of the work; or acquisition, analysis or interpretation of data,
    • Drafted the article or revised it critically for important intellectual content,
    • Approved the version to be published,
    • Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content.

    Authors should meet the conditions of all of the points above. When a large, multicentre group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript. These individuals should fully meet the criteria for authorship.

    Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship, although all contributors who do not meet the criteria for authorship should be listed in the Acknowledgments section. Please refer to the International Committee of Medical Journal Editors (ICMJE) authorship guidelines for more information on authorship.

     4.3 Acknowledgements

    All contributors who do not meet the criteria for authorship should be listed in an Acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, or a department chair who provided only general support.

    Any acknowledgements should appear first at the end of your article prior to your Declaration of Conflicting Interests (if applicable), any notes and your References.

    4.3.1 Writing assistance

    Individuals who provided writing assistance, e.g. from a specialist communications company, do not qualify as authors and so should be included in the Acknowledgements section. Authors must disclose any writing assistance – including the individual’s name, company and level of input – and identify the entity that paid for this assistance. It is not necessary to disclose use of language polishing services.

    4.4 Funding

    The International Journal of Biological Markers requires all authors to acknowledge their funding in a consistent fashion under a separate heading.  Please visit the Funding Acknowledgements page on the SAGE Journal Author Gateway to confirm the format of the acknowledgment text in the event of funding, or state that: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. 

    4.5 Declaration of conflicting interests

    It is the policy of The International Journal of Biological Markers to require a declaration of conflicting interests from all authors enabling a statement to be carried within the paginated pages of all published articles.

    Please ensure that a ‘Declaration of Conflicting Interests’ statement is included at the end of your manuscript, after any acknowledgements and prior to the references. If no conflict exists, please state that ‘The Author(s) declare(s) that there is no conflict of interest’.

    For guidance on conflict of interest statements, please see the ICMJE recommendations here

    4.6 Research ethics and patient consent

    Medical research involving human subjects must be conducted according to the World Medical Association Declaration of Helsinki

    Submitted manuscripts should conform to the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, and all papers reporting animal and/or human studies must state in the methods section that the relevant Ethics Committee or Institutional Review Board provided (or waived) approval. Please ensure that you have provided the full name and institution of the review committee, in addition to the approval number.

    For research articles, authors are also required to state in the methods section whether participants provided informed consent and whether the consent was written or verbal.

    Information on informed consent to report individual cases or case series should be included in the manuscript text. A statement is required regarding whether written informed consent for patient information and images to be published was provided by the patient(s) or a legally authorized representative.

    Please also refer to the ICMJE Recommendations for the Protection of Research Participants

    All research involving animals submitted for publication must be approved by an ethics committee with oversight of the facility in which the studies were conducted. . Experimental research performed on animals must comply with the NIH Guide for the Care and Use of Laboratory Animals or equivalent. A statement that research has been performed according to the NIH Guidelines must be included in the Methods section.

    4.7 Clinical trials

    The International Journal of Biological Markers endorses the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment. However, consistent with the AllTrials campaign, retrospectively registered trials will be considered if the justification for late registration is acceptable. The trial registry name and URL, and registration number must be included at the end of the abstract.

    4.8 Reporting guidelines

    The relevant EQUATOR Network reporting guidelines should be followed depending on the type of study. For example, all randomized controlled trials submitted for publication should include a completed CONSORT flow chart as a cited figure and the completed CONSORT checklist should be uploaded with your submission as a supplementary file. Systematic reviews and meta-analyses should include the completed PRISMA flow chart as a cited figure and the completed PRISMA checklist should be uploaded with your submission as a supplementary file. The EQUATOR wizard can help you identify the appropriate guideline.

    Other resources can be found at NLM’s Research Reporting Guidelines and Initiatives

    4.9 Data 

    SAGE acknowledges the importance of research data availability as an integral part of the research and verification process for academic journal articles.

    The International Journal of Biological Markers requests all authors submitting any primary data used in their research articles alongside their article submissions to be published in the online version of the journal, or provide detailed information in their articles on how the data can be obtained. This information should include links to third-party data repositories or detailed contact information for third-party data sources. Data available only on an author-maintained website will need to be loaded onto either the journal’s platform or a third-party platform to ensure continuing accessibility. Examples of data types include but are not limited to statistical data files, replication code, text files, audio files, images, videos, appendices, and additional charts and graphs necessary to understand the original research. The editor can also grant exceptions for data that cannot legally or ethically be released. All data submitted should comply with Institutional or Ethical Review Board requirements and applicable government regulations. For further information, please contact the editorial office at: journal.biomarkers@aulss3.veneto.it
     

    Back to top

    5. Publishing Policies

    5.1 Publication ethics

    SAGE is committed to upholding the integrity of the academic record. We encourage authors to refer to the Committee on Publication Ethics’ International Standards for Authors and view the Publication Ethics page on the SAGE Author Gateway

    5.1.1 Plagiarism

    The International Journal of Biological Markers and SAGE take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. We seek to protect the rights of our authors and we always investigate claims of plagiarism or misuse of published articles. Equally, we seek to protect the reputation of the journal against malpractice. Submitted articles may be checked with duplication-checking software. Where an article, for example, is found to have plagiarised other work or included third-party copyright material without permission or with insufficient acknowledgement, or where the authorship of the article is contested, we reserve the right to take action including, but not limited to: publishing an erratum or corrigendum (correction); retracting the article; taking up the matter with the head of department or dean of the author's institution and/or relevant academic bodies or societies; or taking appropriate legal action.

    5.1.2 Prior publication

    If material has been previously published it is not generally acceptable for publication in a SAGE journal. However, there are certain circumstances where previously published material can be considered for publication. Please refer to the guidance on the SAGE Author Gateway or if in doubt, contact the Editor at the address given below.

    5.2 Contributor's publishing agreement

    Before publication SAGE requires the author as the rights holder to sign a Journal Contributor’s Publishing Agreement.  The International Journal of Biological Markers publishes manuscripts under Creative Commons licenses. The standard license for the journal is Creative Commons by Attribution Non-Commercial (CC BY-NC), which allows others to re-use the work without permission as long as the work is properly referenced and the use is non-commercial. For more information, you are advised to visit SAGE's OA licenses page.

    Alternative license arrangements are available, for example, to meet particular funder mandates, made at the author’s request. 

    Back to top

     

    6. Preparing your manuscript for submission

    6.1 Formatting

    The preferred format for your manuscript is Word. LaTeX files are also accepted. Word and (La)Tex templates are available on the Manuscript Submission Guidelines page of our Author Gateway.

    6.2 Artwork, figures and other graphics

    For guidance on the preparation of illustrations, pictures and graphs in electronic format, please visit SAGE’s Manuscript Submission Guidelines  

    Figures supplied in colour will appear in colour online regardless of whether or not these illustrations are reproduced in colour in the printed version. For specifically requested colour reproduction in print, you will receive information regarding the costs from SAGE after receipt of your accepted article.

    6.3 Supplementary material

    This journal is able to host additional materials online (e.g. datasets, podcasts, videos, images etc) alongside the full-text of the article. For more information please refer to our guidelines on submitting supplementary files

    6.4 Reference style

    The International Journal of Biological Markers adheres to the SAGE Vancouver reference style. View the SAGE Vancouver guidelines to ensure your manuscript conforms to this reference style.

     If you use EndNote to manage references, you can download the SAGE Vancouver EndNote output file

    6.5 English language editing services

    Authors seeking assistance with English language editing, translation, or figure and manuscript formatting to fit the journal’s specifications should consider using SAGE Language Services. Visit SAGE Language Services on our Journal Author Gateway for further information.

    Back to top

     

    7. Submitting your manuscript

    The International Journal of Biological Markers is hosted on SAGE track, a web based online submission and peer review system. Visit https://mc.manuscriptcentral.com/tijbm to login and submit your article online.

    IMPORTANT: Please check whether you already have an account in the system before trying to create a new one. If you have reviewed or authored for the journal in the past year it is likely that you will have had an account created.  For further guidance on submitting your manuscript online please visit ScholarOne Online Help.

    7.1 Title, keywords and abstracts

    Please supply a title, short title, an abstract and keywords to accompany your article. The title, keywords and abstract are key to ensuring readers find your article online through online search engines such as Google. Please refer to the information and guidance on how best to title your article, write your abstract and select your keywords by visiting the SAGE Journal Author Gateway for guidelines on How to Help Readers Find Your Article Online. 

    7.2 Information required for completing your submission

    Provide full contact details for the corresponding author including email, mailing address and telephone numbers. Academic affiliations are required for all co-authors. These details should be presented separately to the main text of the article to facilitate anonymous peer review.

    You will be asked to provide contact details and academic affiliations for all co-authors via the submission system and identify who is to be the corresponding author. These details must match what appears on your manuscript. At this stage please ensure you have included all the required statements and declarations and uploaded any additional supplementary files (including reporting guidelines where relevant).

    7.3 ORCID

    As part of our commitment to ensuring an ethical, transparent and fair peer review process SAGE is a supporting member of ORCID, the Open Researcher and Contributor ID. 

    ORCID provides a unique and persistent digital identifier that distinguishes researchers from every other researcher, even those who share the same name, and, through integration in key research workflows such as manuscript and grant submission, supports automated linkages between researchers and their professional activities, ensuring that their work is recognized.  

    The collection of ORCID iDs from corresponding authors is now part of the submission process of this journal. If you already have an ORCID iD you will be asked to associate that to your submission during the online submission process. We also strongly encourage all co-authors to link their ORCID ID to their accounts in our online peer review platforms. It takes seconds to do: click the link when prompted, sign into your ORCID account and our systems are automatically updated. Your ORCID iD will become part of your accepted publication’s metadata, making your work attributable to you and only you. Your ORCID iD is published with your article so that fellow researchers reading your work can link to your ORCID profile and from there link to your other publications.

    If you do not already have an ORCID iD please follow this link to create one or visit our ORCID homepage to learn more.

    7.4 Permissions

    Authors are responsible for obtaining permission from copyright holders for reproducing any illustrations, tables, figures or lengthy quotations previously published elsewhere. For further information including guidance on fair dealing for criticism and review, please visit our Frequently Asked Questions on the SAGE Journal Author Gateway.

    Back to top

    8. On acceptance and publication

    If your paper is accepted for publication after peer review, you will first be asked to complete the contributor’s publishing agreement. Once your manuscript files have been checked for SAGE Production, the corresponding author will be asked to pay the article processing charge (APC) via a payment link. Once the APC has been processed, your article will be prepared for publication and can appear online within an average of 30 days. Please note that no production work will occur on your paper until the APC has been received. 

    8.1 SAGE Production

    Your SAGE Production Editor will keep you informed as to your article’s progress throughout the production process. Proofs will be sent by PDF to the corresponding author and should be returned promptly.  Authors are reminded to check their proofs carefully to confirm that all author information, including names, affiliations, sequence and contact details are correct, and that Funding and Conflict of Interest statements, if any, are accurate. Please note that if there are any changes to the author list at this stage all authors will be required to complete and sign a form authorising the change.

    8.2 Online publication

    One of the many benefits of publishing your research in an open access journal is the speed to publication. With no page count constraints, your article will be published online in a fully citable form with a DOI number as soon as it has completed the production process. At this time it will be completely free to view and download for all.

    8.3 Promoting your article

    Publication is not the end of the process! You can help disseminate your paper and ensure it is as widely read and cited as possible. The SAGE Author Gateway has numerous resources to help you promote your work. Visit the Promote Your Article page on the Gateway for tips and advice. In addition, SAGE is partnered with Kudos, a free service that allows authors to explain, enrich, share, and measure the impact of their article. Find out how to maximise your article’s impact with Kudos

    Back to top

    9. Further information

    Any correspondence, queries or additional requests for information on the manuscript submission process should be sent to The International Journal of Biological Markers editorial office as follows: journal.biomarkers@aulss3.veneto.it